Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.

136 After 16 weeks of treatment, there were no differences in the primary outcome measures assessing episodic and spatial memory between the memantine group and the placebo controls; however, there was a marginally significant outcome in one secondary memory measurement. 136 Results of a small trial with the green tea component, EGCG, were recently reported. 84 Fifteen participants aged 14–29 years were treated with EGCG for 3 months.

also in 26,082 other papers